Loading...
Fluvastatin mitigates SARS-CoV-2 infection in human lung cells.
Zapatero-Belinchón, Francisco J Moeller, Rebecca Lasswitz, Lisa van Ham, Marco Becker, Miriam Brogden, Graham Rosendal, Ebba Bi, Wenjie Carriquí-Madroñal, Belén Islam, Koushikul
Zapatero-Belinchón, Francisco J
Moeller, Rebecca
Lasswitz, Lisa
van Ham, Marco
Becker, Miriam
Brogden, Graham
Rosendal, Ebba
Bi, Wenjie
Carriquí-Madroñal, Belén
Islam, Koushikul
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2021-11-18
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 4.81 MB
Other Titles
Abstract
Clinical data of patients suffering from COVID-19 indicates that statin therapy, used to treat hypercholesterolemia, is associated with a better disease outcome. Whether statins directly affect virus replication or influence the clinical outcome through modulation of immune responses is unknown. We therefore investigated the effect of statins on SARS-CoV-2 infection in human lung cells and found that only fluvastatin inhibited low and high pathogenic coronaviruses in vitro and ex vivo in a dose-dependent manner. Quantitative proteomics revealed that fluvastatin and other tested statins modulated the cholesterol synthesis pathway without altering innate antiviral immune responses in infected lung epithelial cells. However, fluvastatin treatment specifically downregulated proteins that modulate protein translation and viral replication. Collectively, these results support the notion that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that fluvastatin has a moderate beneficial effect on SARS-CoV-2 infection of human lung cells.
Citation
. iScience. 2021 Dec 17;24(12):103469. doi: 10.1016/j.isci.2021.103469. Epub 2021 Nov 18.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
2589-0042
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution 4.0 International